Drug Type Antibody drug conjugate (ADC) |
Synonyms BCG022 |
Target |
Mechanism HER3 modulators(Receptor tyrosine-protein kinase erbB-3 modulators), Tubulin inhibitors, c-Met modulators(Hepatocyte growth factor receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H67N5O7 |
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N |
CAS Registry474645-27-7 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 14 Apr 2023 |